Percutaneous Metallic Stents in Malignant Biliary Obstruction: Comparison of Nitinol and Wall Stents

• Published in: Journal of gastrointestinal cancer 2024-09, Vol.55 (3), p.1425-1432
• Main Authors: Koska, İlker Özgür, Akıncı, Devrim, Akhan, Okan
• Format: Article
• Language: English
• Subjects: Cancer Research; Gastroenterology; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Radiotherapy
• ISSN: 1941-6628; 1941-6636; 1941-6636
• DOI: 10.1007/s12029-024-01101-y

Introduction Palliation of malign biliary obstruction is important which is commonly carried out by percutaneous biliary stenting. Our primary aim with this study was assessment of performance of wall stents, and nitinol stents for the palliation of malign biliary obstruction. Methods The medical records of 157 patients who underwent biliary stenting in our department between January 1, 1995, and December 31, 2005, were retrospectively analyzed. Technical success, treatment success, mortality in the first 30 days, minor, and major complications were evaluated and compared among the wall stent, and the nitinol stent groups in all patients which constituted the primary study endpoints. Additionally, stent patency, and mean patient survival times after stent implantation were evaluated in patients for whom follow-up information could be obtained. Results A total of 213 metallic stents were placed in 157 patients. Wall stent was placed in 83 of the patients with mean age, and SD of 60.4 and 13.5. Nitinol stent was placed in 74 of the patients with mean age of 57.8, and SD of 15.5. Gender ratio was equal in both groups. Biliary stent dysfunction was observed in 13 patients in each of nitinol, and wall stent groups throughout the study period. There was no statistical difference among re-occlusion rates ( p  = 0.91). For the nitinol stent group median primary patency time was 119 days (90–185 days CI 95%), and for the wall stent group median primary patency time was 81 days (60–150 days CI 95%). Conclusion Nitinol stents, and wall stents are safe options that can be safely used in the percutaneous treatment of malignant biliary obstruction with similar treatment and therapeutic success, low complication rates, and patency times that can extend beyond expected survival times.